![PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo] PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]](https://i1.rgstatic.net/publication/6236886_Early_immunotherapy_in_MS_reduces_the_risk_of_later_disability_The_secondary_progressive_course_is_delayed_according_to_a_study_with_virtual_placebo/links/0a85e5386630b0e26c000000/largepreview.png)
PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]
![PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo] PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]](https://www.researchgate.net/profile/Leszek-Stawiarz/publication/6236886/figure/fig2/AS:601772670337039@1520485193545/Figur-2-Jaemfoerelse-av-tid-till-progress-mellan-patienter-med-ett-debutskov-Vaenster_Q320.jpg)
PDF) [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]
![In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish) In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)](https://www.jove.com/files/ftp_upload/62811/62811fig03large.jpg)
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)
![In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish) In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)](https://www.jove.com/files/ftp_upload/62811/62811fig01large.jpg)
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)
![In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish) In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)](https://cloudfront.jove.com/files/ftp_upload/62811/62811fig01.jpg)
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells | Protocol (Translated to Swedish)
![Interferons as biomarkers and effectors: lessons learned from animal models | Biomarkers in Medicine Interferons as biomarkers and effectors: lessons learned from animal models | Biomarkers in Medicine](https://www.futuremedicine.com/cms/10.2217/bmm.12.10/asset/images/medium/figure1.gif)